Added to YB: 2026-09-14
Pitch date: 2026-09-10
BCRX [bullish]
BioCryst Pharmaceuticals, Inc.
Author Info
No bio for this author
Company Info
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Market Cap
$2.2B
Pitch Price
N/A
Price Target
14.00
Dividend
N/A
EV/EBITDA
6.28
P/E
-5.25
EV/Sales
2.91
Sector
Biotechnology
Category
value
$BCRX Long Idea
BCRX: At $8, BioCryst offers a $9.25 short-term target and $14+ longer-term target; its ~$2B market cap is roughly 3x current product sales, and the company is projected to generate at least two more years of ~$200M+ annual operating profit before deucrictibant launches. Navenibart’s Q3 2027 readout could provide a long-acting competitive response before Pharvaris’s anticipated 2028 approval.
Read full article (2 min)